Fineline Cube

Follow:
14482 Articles
CompanyDrug

Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer

CompanyDrug

Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma

CompanyDrug

InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis

CompanyDrug

Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss – Androgen Receptor Antagonist Tincture Shows 15.33 Hairs/cm² Growth vs. Placebo

Medical Device

Super Vision Technology Wins NMPA Approval for Ocular Neurostimulator – First-in-Class Implantable Device Treats Congenital Nystagmus

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities
CompanyDeals

GE HealthCare Closes $2.3 Billion Intelerad Acquisition – Medical Imaging Software Deal Expands Ambulatory and Cloud-First Capabilities

CompanyDeals

Leveragen Partners with Daiichi Sankyo – In Vivo Antibody Discovery Collaboration Targets Advanced Biologics

J&J's Icotyde Wins FDA Approval – First Oral IL-23 Receptor Antagonist Targets Moderate-to-Severe Plaque Psoriasis
CompanyDrug

J&J’s Icotyde Wins FDA Approval – First Oral IL-23 Receptor Antagonist Targets Moderate-to-Severe Plaque Psoriasis

Sanofi's Venglustat Wins FDA Breakthrough Therapy Designation – Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms
CompanyDrug

Sanofi’s Venglustat Wins FDA Breakthrough Therapy Designation – Oral Brain-Penetrant GCSi Targets Gaucher Disease Type 3 Neurological Symptoms

CompanyDeals

Medbanks Acquires Jianyi Tech for RMB 360 Million – Insurance-Tech Deal Strengthens Corporate Health Security Platform

CompanyDrug

TransThera Sciences Doses First Patient in Phase II Tinengotinib Combination Study – Multi-Kinase Inhibitor Plus Fulvestrant Targets HR+/HER2- Breast Cancer

CompanyDeals

Walvax Bio Raises RMB 2 Billion via Private Placement – Tengyun Xinwo Bio to Become Controlling Shareholder